Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2026
Reporting Period: The filing primarily addresses a material definitive agreement entered into on May 12, 2026. It also references the Company's financial results for the first quarter ended March 31, 2026, which were announced via press release on May 13, 2026.
Key Financial Metrics and Capital Structure
Debt Facility: Entered into a five-year term loan facility with a total capacity of up to $150.0 million with Oaktree Capital Management funds.
Initial Funding (Tranche A): $55.0 million funded on the Effective Date.
Existing Debt Repaid: $45.0 million outstanding under a previous indenture was repaid in full using proceeds from Tranche A.
Interest Rate: Three-month SOFR (floor 2.75%) plus 6.25%. Interest-only payments quarterly until maturity.
Collateral: Secured by a lien on substantially all Company assets, including intellectual property.
Equity Issuance: Warrants issued to lenders equal to 1.75% of the principal amount of drawn tranches, divided by the applicable 30-day VWAP.
Material Changes Versus Prior Period
- Debt Refinancing: The Company terminated its previous $45.0 million note indenture and replaced it with the new $150.0 million facility.
- Liquidity Position: The Company received $55.0 million in immediate cash proceeds, net of the $45.0 million debt repayment and associated fees.
- Covenants: New financial covenants require maintaining minimum unrestricted cash levels ($27.5 million initially, reducing to $15.0 million after Tranche B funding) and meeting minimum net sales targets post-approval.
Guidance, Outlook, and Risks
Future Funding Tranches:
- Tranche B ($20.0 million): Available upon FDA approval of Anaphylm prior to June 30, 2027.
- Tranche C ($25.0 million): Available upon achieving a specified net sales milestone by December 31, 2027.
- Tranche D (up to $50.0 million): Available upon mutual consent of Lenders and Company.
Risks and Contingencies:
- FDA Approval Risk: If FDA approval for Anaphylm is not received by December 31, 2027, the Company may be required to prepay a portion of the loan, and the minimum cash covenant may be reduced dollar-for-dollar.
- Prepayment Penalties: Voluntary prepayment prior to the first anniversary includes a make-whole fee; prepayment between the first and fourth anniversary incurs a premium ranging from 5.00% to 1.00%.
- Exit Fee: Repayment at maturity or acceleration triggers an exit fee ranging from 1.00% to 2.00%.
Financial Results: The filing references Q1 2026 results but does not contain specific revenue, profit, or cash flow figures within the text provided; these are contained in attached exhibits.
Investor Verification Checklist
- Verify the specific Q1 2026 revenue and cash burn figures in the attached Press Release (Exhibit 99.1).
- Confirm the current status of the Anaphylm New Drug Application and the likelihood of FDA approval by June 30, 2027.
- Review the specific "Minimum Net Sales Covenant" thresholds detailed in the Credit Agreement schedules.
- Assess the dilution impact of the warrants issued to Oaktree funds based on the 30-day VWAP at the time of funding.
- Monitor the Company's unrestricted cash balance to ensure compliance with the $27.5 million minimum covenant requirement.